Pharmarise Holdings Corporation
2796.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 5.37 | 0.10 | -0.66 | 3.28 |
| FCF Yield | 11.09% | 30.86% | 34.44% | 3.64% |
| EV / EBITDA | 8.85 | 8.98 | 4.36 | 4.72 |
| Quality | ||||
| ROIC | -61.72% | -10.13% | 2.76% | 2.97% |
| Gross Margin | 14.12% | 15.51% | 15.63% | 15.73% |
| Cash Conversion Ratio | 163.88 | -7.73 | 2.40 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.87% | 1.81% | -0.19% | 0.38% |
| Free Cash Flow Growth | -70.93% | 5.92% | 700.81% | -82.27% |
| Safety | ||||
| Net Debt / EBITDA | 5.58 | 4.06 | 1.89 | 2.20 |
| Interest Coverage | 1.65 | 13.88 | 26.15 | 23.38 |
| Efficiency | ||||
| Inventory Turnover | 13.16 | 17.40 | 19.17 | 18.89 |
| Cash Conversion Cycle | 5.03 | -0.32 | 11.91 | 15.03 |